Literature DB >> 17502343

Current treatment of hepatitis B.

G Dusheiko1, N Antonakopoulos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17502343     DOI： 10.1136/gut.2005.077891

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  4 in total

1.  HBV life cycle and novel drug targets.

Authors:  Daniel Grimm; Robert Thimme; Hubert E Blum
Journal:  Hepatol Int       Date:  2011-03-08       Impact factor: 6.047

2.  Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

Authors:  Pham Thi Le Hoa; Nguyen Tien Huy; Le The Thu; Cao Ngoc Nga; Kazuhiko Nakao; Katsumi Eguchi; Nguyen Huu Chi; Bui Huu Hoang; Kenji Hirayama
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

3.  Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.

Authors:  Sung Soo Ahn; Young Eun Chon; Beom Kyung Kim; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Jun Yong Park
Journal:  Clin Mol Hepatol       Date:  2014-09-25

4.  How to compare antivirals in the treatment of chronic hepatitis B?

Authors:  Resat Ozaras; Hakan Leblebicioglu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-03-02       Impact factor: 3.944
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.